The effect of probucol therapy on long-term survival following complete revascularization was also reported in 1,694 patients after complete revascularization with PCI and/or CABG by a propensity score analysis 45 ) , in which the use of probucol was associated with a markedly significant decrease in all-cause death in a propensity score-adjusted model (hazard ratio = 0.57; p = 0.008).
As a note, although the differences did not reach statistical significance, the numbers of patients (%) tended to be decreased in the test group, compared with those in the control group, in the incidence of the key composites of the primary end point of cerebrovascular and cardiovascular events except nonfatal stroke excluding transient ischemic attack; death because of
Results: The incidence of the primary end point showed a trend to be lower in the probucol group compared with that in the control group despite reduced HDL-C without serious adverse events.